| 达比加群酯的临床药理及其预防心房颤动患者卒中的研究进展 |
| |
| 引用本文： | 章殷希,丁美萍. 达比加群酯的临床药理及其预防心房颤动患者卒中的研究进展[J]. 中国新药杂志, 2012, 0(11): 1227-1231,1236 |
| |
| 作者姓名： | 章殷希 丁美萍 |
| |
| 作者单位： | 浙江大学医学院附属第二医院神经内科 |
| |
| 摘 要： | 达比加群酯是近几年上市的一种新型口服抗凝药物,最初用于预防关节置换术后血栓的形成。美国FDA于2010年10月批准达比加群酯用于预防心房颤动患者的脑卒中。本文对其药理作用、药代动力学、临床疗效评价及不良反应等做一综述。
|
| 关 键 词： | 达比加群酯 口服抗凝剂 药理作用 药代动力学 临床疗效评价 不良反应 |
Dabigatran etexilate,a novel oral anticoagulant for stroke prevention in patients with atrial fibrillation |
| |
| ZHANG Yin-xi,DING Mei-ping. Dabigatran etexilate,a novel oral anticoagulant for stroke prevention in patients with atrial fibrillation[J]. Chinese Journal of New Drugs, 2012, 0(11): 1227-1231,1236 |
| |
| Authors: | ZHANG Yin-xi DING Mei-ping |
| |
| Affiliation: | (Department of Neurology,2nd Affiliated Hospital Zhejiang University College of Medicine,Hangzhou 310009,China) |
| |
| Abstract: | Dabigatran etexilate,a novel oral direct thrombin inhibitor that was firstly used in preventing venous thrombo-embolism after arthroplasty,has been proved by the American Food and Drug Administration(FDA) for stroke prevention in patients with atrial fibrillation in October 2010.In this paper,we reviewed the pharmacology,pharmacokinetics,clinical efficacy and safety of dabigatran etexilate. |
| |
| Keywords: | dabigatran etexilate oral anticoagulant pharmacology pharmacokinetics clinical efficacy evaluation adverse reaction |
| 本文献已被 CNKI 等数据库收录！ |
